CD8A and hepatocellular carcinoma: LGALS9 and IDO1 may serve as targets for improving CSCC therapy, but the impact of myCAFs in this should be considered, as it limits lymphocyte infiltration.[87] To investigate the immune‐depleted tumor immune microenvironment in steatotic HCC, Murai et al.[103] defined CD8A+NR4A1+ spots as depleted cytotoxic T‐lymphocytes (CTLs).